EDWARD MARK SCOLNICK
Medical Practice in Wayland, MA
License number
Pennsylvania MD027859E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Wayland, MA 01778
Pennsylvania
Pennsylvania
Personal information
See more information about EDWARD MARK SCOLNICK at radaris.comName
Address
Phone
1201 Magnolia Dr, Wayland, MA 01778
811 Wickfield Rd, Wynnewood, PA 19096
Dingmans Ferry, PA
Wayland, MA
1201 Magnolia Dr, Wayland, MA 01778
Professional information
Compositions Of Modulators Of The Wnt/Beta-Catenin Pathway And Benzamide And/Or Hydroxamic Acid Derivatives To Treat Bipolar Disorder
US Patent:
2013003, Feb 14, 2013
Filed:
Dec 23, 2009
Appl. No.:
13/141747
Inventors:
Daniel Fass - Winchester MA, US
Stephen Haggarty - Dorchester MA, US
Edward Scolnick - Wayland MA, US
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Stephen Haggarty - Dorchester MA, US
Edward Scolnick - Wayland MA, US
Randall T. Moon - Kenmore WA, US
Travis L. Biechele - Seattle WA, US
Nathan D. Camp - Seattle WA, US
Assignee:
UNIVERSITY OF WASHINGTON - Seattle WA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
International Classification:
A61K 31/167, A61K 31/4406, A61P 25/00, A61K 31/513, A61K 33/14, A61K 33/00, A61K 31/4045, A61K 31/194
US Classification:
424677, 514616, 514415, 514357, 514574, 514274, 424715
Abstract:
The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.